(Q43635735)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11400231%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

title

Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11400231%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

main subject

head and neck carcinoma

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11400231%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Riccardo Ragona

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11400231%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

author name string

M Airoldi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11400231%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

A De Stefani

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11400231%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

S Marchionatti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11400231%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

F Pedani

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11400231%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

G Cortesina

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11400231%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

C Bumma

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11400231%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

publication date

1 April 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11400231%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11400231%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11400231%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11400231%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

page(s)

298-304

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11400231%20AND%20SRC:MED&resulttype=core&format=json

Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck

8 November 2019

cites work

1 reference

Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically

21 January 2018

1 reference

A phase II study of interleukin-2 and interferon-alpha in head and neck cancer

21 January 2018

1 reference

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies

21 January 2018

1 reference

Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha

21 January 2018

1 reference

Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-gamma in oral cancer patients

21 January 2018

1 reference

Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells

21 January 2018

1 reference

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha

21 January 2018

1 reference

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

21 January 2018

1 reference

Chemoimmunotherapy of metastatic malignant melanoma. The Salpétrière Hospital (SOMPS) experience.

21 January 2018

1 reference

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma

21 January 2018

1 reference

Local Administration Trials of Interleukin-2 for Head and Neck Cancer

21 January 2018

1 reference

The in vivo biologic effect of interleukin 2 and interferon alfa on natural immunity in patients with head and neck cancer

21 January 2018

1 reference

Augmentation of the lymphokine-activated killer cell response in head and neck cancer patients by combination interleukin-2 and interferon-alpha

21 January 2018

1 reference

Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation

21 January 2018

1 reference

In vitro and in vivo effects of cisplatin on the generation of lymphokine-activated killer cells

21 January 2018

1 reference

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

21 January 2018

1 reference

A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group

21 January 2018

1 reference

Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas.

21 January 2018

1 reference

7 January 2021

Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer

1 reference

7 January 2021

Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial

1 reference

7 January 2021

Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HED.1034

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11400231%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1 reference